User login
CurePSP and the Tau Consortium, leading foundations fighting neurodegenerative disease, have brought together a team of prominent investigators who will launch the definitive study of the gene variants involved in progressive supranuclear palsy (PSP). PSP is a deadly brain disorder that afflicts about 20,000 people in the US and is a leading target for researchers seeking to understand all neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases.
CurePSP and the Tau Consortium, leading foundations fighting neurodegenerative disease, have brought together a team of prominent investigators who will launch the definitive study of the gene variants involved in progressive supranuclear palsy (PSP). PSP is a deadly brain disorder that afflicts about 20,000 people in the US and is a leading target for researchers seeking to understand all neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases.
CurePSP and the Tau Consortium, leading foundations fighting neurodegenerative disease, have brought together a team of prominent investigators who will launch the definitive study of the gene variants involved in progressive supranuclear palsy (PSP). PSP is a deadly brain disorder that afflicts about 20,000 people in the US and is a leading target for researchers seeking to understand all neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases.
